- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06208657
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: National Study Coordinator
- Phone Number: +61293821730
- Email: SCHN-OPTIMISE@health.nsw.gov.au
Study Contact Backup
- Name: KOALA Manager
- Email: SCHN-OPTIMISE@health.nsw.gov.au
Study Locations
-
-
New South Wales
-
Newcastle, New South Wales, Australia
- John Hunter Children's Hospital
-
Contact:
- Rebecca Jensen
- Email: Rebecca.Jensen@health.nsw.gov.au
-
Sydney, New South Wales, Australia
- Sydney Children's Hospital, Randwick
-
Contact:
- Sarah Montez
- Email: Sandra.Montez@health.nsw.gov.au
-
Sydney, New South Wales, Australia
- The Children's Hospital at Westmead
-
Contact:
- Jun Christian
- Email: jun.christian@health.nsw.gov.au
-
-
Queensland
-
Brisbane, Queensland, Australia
- Queensland Children's Hospital
-
Contact:
- Natasha Brown
- Email: natasha.brown@health.qld.gov.au
-
-
South Australia
-
Adelaide, South Australia, Australia
- Women's and Children's Hospital
-
Contact:
- Amy Rudge
- Email: amy.rudge@sa.gov.au
-
-
Victoria
-
Melbourne, Victoria, Australia
- Royal Children's Hospital
-
Contact:
- Kahlia Fox
- Email: clinicaltrialsmanager@rch.org.au
-
Melbourne, Victoria, Australia
- Monash Children's Hospital
-
Contact:
- Amanda St John
- Email: Amanda.StJohn@monashhealth.org
-
-
Western Australia
-
Perth, Western Australia, Australia
- Perth Children's Hospital
-
Contact:
- Jennifer McConnell
- Email: jennifer.mcconnell@health.wa.gov.au
-
-
-
-
-
Montréal, Canada
- CHU Sainte Justine
-
Contact:
- Annie Lahaye
- Email: annie.lahaye.hsj@ssss.gouv.qc.ca
-
Toronto, Canada
- The Hospital for Sick Children
-
Contact:
- Aiman Siddiqi
- Email: aiman.siddiqi@sickkids.ca
-
Vancouver, Canada
- BC Children's Hospital
-
Contact:
- Peter Subrt
- Email: psubrt@bcchr.ca
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients must be diagnosed with a solid tumor, CNS tumor or lymphoma that has progressed despite standard therapy, or for which no effective standard therapy exists.
- Age <21 years at inclusion; patients 21 years and older may be included after approval by the Study Chair if they have a pediatric type recurrent/refractory malignancy.
- Patients must be enrolled on a precision medicine study (i.e. PROFYLE, ZERO or equivalent as agreed with Study Chair.
- Patients enrolled in a Phase I cohort must have either evaluable or measurable disease.
- Patients enrolled in a Phase II cohort must have measurable disease. Evaluable and measurable disease are defined by standard imaging criteria for the patient's tumor type.
- Disease evaluations, laboratory tests, and other clinical assessments that are considered standard of care may be undertaken at the patient's local oncology treatment centre with results transferred to study site for evaluation.
- Performance status: Karnofsky performance status (for patients > 16 years of age) or Lansky play score (for patients ≤ 16 years of age) ≥ 50%.
- Life expectancy ≥ 6 weeks.
- Patients must have fully recovered from the acute toxic effects of all prior anticancer therapy and must meet the following minimum duration from prior anticancer-directed therapy prior to enrolment.
- Adequate organ function.
- Able to comply with scheduled follow-up and with management of toxicity.
- Females of childbearing potential must have a negative serum or urine pregnancy test.
- Fertile males must agree to use adequate contraception during the study and following completion of treatment.
- Provide a signed and dated informed consent form.
Exclusion Criteria:
- Patients with symptomatic CNS primary or metastatic tumors who are neurologically unstable or require increasing doses of corticosteroids or local CNS-directed therapy to control their CNS disease.
- Impairment of gastrointestinal (GI) function or GI disease that may significantly alter drug absorption of oral drugs.
- Clinically significant, uncontrolled heart disease.
- Known active viral hepatitis or human immunodeficiency virus (HIV) infection or any other uncontrolled infection.
- Presence of any ≥Grade 2 treatment-related toxicity.
- Major surgery within 21 days of the first dose of investigational drug.
- Known hypersensitivity to any study drug or component of the formulation.
- Pregnant or nursing (lactating) females.
- Any other concomitant serious medical condition or organ dysfunction that in the opinion of the investigator would either compromise patient safety or interfere with the evaluation of the safety of the investigational drugs.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm A Paxalisib
Drug: Irinotecan Drug: Temozolomide Drug: Paxalisib Irinotecan 50mg/m2/day, intravenous, on days 1-5, 28 day cycle, 13 cycles Temozolomide 150mg/m2/day, oral, on days 1-5, 28 day cycle, 13 cycles Paxalisib 21mg/m2 oral, daily, 28 day cycle, 13 cycles
|
Irinotecan 50mg/m2/day, intravenous, on days 1-5, 28 day cycle, 13 cycles Temozolomide 150mg/m2/day, oral, on days 1-5, 28 day cycle, 13 cycles Paxalisib 21mg/m2 oral, daily, 28 day cycle, 13 cycles
|
Experimental: Arm B Pimasertib
Drug: Pimasertib Pimasertib 28mg/m2 oral, twice daily, 28 day cycle, 26 cycles
|
Pimasertib 28mg/m2 oral, twice daily, 28 day cycle, 26 cycles
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants treated with molecularly-targeted agents in each treatment arm.
Time Frame: 5 Years
|
Number of CAYA participants (children, adolescents and young adults) with advanced solid tumours (including CNS tumors and non-Hodgkin lymphomas) where molecular sequencing data was used to allocate treatment arms of molecularly-targeted agents.
|
5 Years
|
Recommended phase II dose for each treatment arm
Time Frame: 3 Years
|
Recommended phase II dose of a novel single agent or combination treatment in CAYA participants, determined by dose-limiting toxicities reported as per CTCAE V5.0.
|
3 Years
|
Objective Response Rate (ORR) for each treatment arm.
Time Frame: 5 Years
|
ORR defined as complete response and partial response, as measured by RECIST, RAPNO, INRC or RECIL in CAYA participants treated with molecularly-targeted agents.
|
5 Years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Clinical Benefit Rate (CBR) for each treatment arm
Time Frame: 5 Years
|
CBR defined as complete response and partial response and stable disease, as measured by RECIST, RAPNO, INRC or RECIL in CAYA participants treated with molecularly-targeted agents.
|
5 Years
|
Progression Free Survival (PFS) for each treatment arm.
Time Frame: 5 Years
|
PFS in CAYA participants from initiation of treatment with molecularly-targeted agents to the occurrence of disease progression, as measured by RECIST, RAPNO, INRC or RECIL, or death.
|
5 Years
|
Incidence of treatment-emergent adverse events for each treatment arm.
Time Frame: 5 Years
|
Safety and tolerability of molecularly-targeted agents as measured by incidence of treatment-emergent adverse events reported as per CTCAE V5.0 in CAYA participants.
|
5 Years
|
Maximum Concentration (Cmax) of molecularly-targeted agents for each treatment arm.
Time Frame: 5 Years
|
Cmax in plasma after the first dose of molecularly-targeted agents in CAYA participants.
|
5 Years
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: David Ziegler, Prof, Sydney Children's Hospital - Australian Study Chair
- Study Chair: Daniel Morgenstern, Dr, The Hospital for Sick Children - Canadian Study Chair
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- OPTIMISE
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Plan to Share IPD: Neither the complete nor any part of the results of the study carried out under this protocol, nor any of the information provided by the Sponsor for the purposes of performing the study, will be published or passed on to any third party without the consent of the Study Committee.
The pseudonymized data will be shared for transparency reasons in the context of publications and after publication with other physicians and scientists (national and international academia) to promote and accelerate research on causes and treatment development of oncological diseases.
Requests for access to pseudonymized patient data for other scientific purposes will be reviewed by the Study Committee. A positive statement of the respective ethic committee and a signed data protection commitment are requested. Results of scientific research based on the study data may be used for academic teaching, research and scientific publications or presentations at scientific meetings.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Childhood Cancer
-
Australian & New Zealand Children's Haematology...Medical Research Future Fund; Minderoo Foundation; Children's Cancer Institute...RecruitingChildhood Cancer | Relapsed Cancer | Refractory Cancer | Childhood Leukemia | Childhood Solid Tumor | Childhood Brain TumorAustralia
-
University of Colorado, DenverRecruitingCancer | Childhood CancerUnited States
-
Children's Hospital of PhiladelphiaCompletedCancer | Childhood CancerUnited States
-
Sydney Children's Hospitals NetworkGerman Cancer Research Center; Australian & New Zealand Children's Haematology... and other collaboratorsActive, not recruitingChildhood Cancer | Relapsed Cancer | Refractory Cancer | Childhood Leukemia | Childhood Solid Tumor | Childhood Brain TumorAustralia
-
Wake Forest University Health SciencesTerminated
-
Gustave Roussy, Cancer Campus, Grand ParisActive, not recruiting
-
Pernille BidstrupOdense University Hospital; Aarhus University Hospital; Aarhus University Hospital... and other collaboratorsCompleted
-
Emory UniversityNational Cancer Institute (NCI)Recruiting
-
Children's Cancer Group, ChinaShanghai Children's Medical Center; Shanghai Municipal Center for Disease Prevention...Recruiting
-
St. Jude Children's Research HospitalRecruiting
Clinical Trials on Paxalisib, Irinotecan, Temozolomide
-
Centre Oscar LambretSFCECompleted
-
Sun Yat-sen UniversityRecruiting
-
Duke UniversityPfizerCompletedGlioblastomaUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
Duke UniversityNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
University of California, San FranciscoNational Cancer Institute (NCI)CompletedBreast Cancer | Metastatic CancerUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingMetastatic Solid Tumor | Advanced CancerUnited States
-
St. Jude Children's Research HospitalNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
Johns Hopkins All Children's HospitalThe V Foundation; Brain Tumor AllianceCompletedCentral Nervous System TumorsUnited States
-
Tianjin Medical University Cancer Institute and...Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruitingRefractory or Recurrent Neuroblastoma in Children